Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer
Background The efficacy and safety of chemotherapy (CTx) after anti-PD-1 therapy in patients with advanced gastric cancer (AGC) remains unclear.Methods Medical records of consecutive patients with AGC treated with both CTx (taxanes plus ramucirumab, taxanes monotherapy or irinotecan) and anti-PD-1 t...
Main Authors: | Saori Mishima, Akihito Kawazoe, Yasutoshi Kuboki, Takashi Kojima, Toshihiko Doi, Takayuki Yoshino, Kohei Shitara, Yoshiaki Nakamura, Kentaro Sawada, Hiroya Taniguchi, Daisuke Kotani, Akinori Sasaki, Testuya Eto, Mashiro Okunaka, Tetsuo Akimoto |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-10-01
|
Series: | ESMO Open |
Online Access: | https://esmoopen.bmj.com/content/5/4/e000775.full |
Similar Items
-
Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer
by: Mashiro Okunaka, et al.
Published: (2020-11-01) -
A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites
by: Hiroshi Matsumoto, et al.
Published: (2018-01-01) -
Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer
by: Takahiro Ishii, et al.
Published: (2020-07-01) -
Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
by: Saori Mishima, et al.
Published: (2019-01-01) -
Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment
by: Yasuko Tada, et al.
Published: (2018-10-01)